Sanofi Consumer Healthcare India shares jumped in afternoon trade, the top gainer currently, rising 15.41% to Rs. 4,622.95 on the BSE after the company reported a strong set of quarterly and full-year numbers. The stock added Rs. 617.20 over the previous close of Rs. 4,005.75, after moving between Rs. 4,200.10 to 4,806.90 (upper price band), with VWAP at Rs. 4,652.30. Trading volumes stood at about 1.03 lakh shares with turnover of around Rs. 48.12 crore, while the stock’s 52-week range is Rs. 3,967 to 5,954.

The rally followed the company’s results announcement for the quarter ended December 31, 2025 (Q4) and the full year ended December 31, 2025, which pointed to sharp improvement in revenues and profitability, supported by better momentum in the domestic portfolio and a strong rebound in exports from a low base.

For Q4, Sanofi Consumer Healthcare reported revenue of Rs. 251 crore, up 47% YoY, and net profit of Rs. 66.5 crore, up 50%. The company said domestic sales grew 23%, aided by the relaunch of recalled products back into the market, while export sales jumped 9.3x on a low base. For the full year, revenue rose 21% to Rs. 878 crore, while net profit increased 33% to Rs. 240 crore, with domestic sales up 7% and exports up 158% (again aided by the low base effect).

The board declared a dividend of Rs. 75 per share, and management commentary emphasised execution strength and brand-building. The MD said the domestic business has delivered healthy double-digit growth for two successive quarters, supported by export contributions, while the chairman highlighted disciplined execution and the ability to reward shareholders with a healthy payout.

Sanofi Consumer Healthcare India is an over-the-counter (OTC) and self-care focused consumer health company, marketing wellness and healthcare products in India and select export markets.